Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients

Mycopathologia

Volumn 168, Issue 6, 2009, Pages 299-311

  Wirk, Baldeep ^a   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antifungal prophylaxis; Hematological malignancies; Hematopoietic stem cell; Transplantation

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; ASPERGILLOSIS; BLOOD DISEASE; CANDIDIASIS; CLINICAL TRIAL; DEUTEROMYCETES; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PATHOLOGY; PREMEDICATION; RISK FACTOR;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MITOSPORIC FUNGI; PREMEDICATION; RISK FACTORS;

EID: 71449090672     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-009-9188-6     Document Type: Article

References (72)

1. Wingard JR, Leather HL. A new era of antifungal therapy. Biol Blood Marrow Transplant. 2004; 10: 73-90. doi: 10. 1016/j. bbmt. 2003. 09. 014.
2. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2003; 100: 4358-66. doi: 10. 1182/blood-2002-05-1496.
3. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted risk-based anti-fungal strategy in neutropenic patients. Br J Haematol. 2000; 110: 273-84. doi: 10. 1046/j. 1365-2141. 2000. 02014. x.
4. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev. 1997; 10: 444-65.
5. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007; 44: 373-9. doi: 10. 1086/509917.
6. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006; 42: 1417-27. doi: 10. 1086/503427.
7. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1 → 3)-Beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005; 43: 5957-62. doi: 10. 1128/JCM. 43. 12. 5957-5962. 2005.
8. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the anti-leukemic regimen. Clin Infect Dis. 1995; 21: 361-9.
9. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol. 1990; 17: 10-3.
10. Tortorano AM, Kibbler C, Perman J, Bernhardt H, Klingspor L, Grillot R. Candidemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006; 27: 359-66. doi: 10. 1016/j. ijantimicag. 2006. 01. 002.
11. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R, et al. Increase in Candidakrusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991; 326: 1274-7.
12. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC. Candidemia and cancer: patients are not all the same. BMC Infect Dis. 2006; 6: 1-7. doi: 10. 1186/1471-2334-6-50.
13. Gerson SL, Talbot GH, Lusk E, Hurwitz S, Strom BL, Cassileth P. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol. 1985; 3: 1109-16.
14. Talbot GH, Weiner MH, Gerson SL, Provencher M, Hurwitz S. Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillusfumigatus antigen radioimmunoassay. J Infect Dis. 1987; 155: 12-27.
15. Winston D, Chandrasekar P, Lazarus H, Goodman J, Silber J, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind nulticenter trial. Ann Intern Med. 1993; 118: 495-503.
16. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999; 28: 331-40. doi: 10. 1086/515128.
17. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006; 91: 1068-75.
18. Borlenghi E, Cattaneo C, Capucci M, Pan A, Quaresmini G, Franco F, et al. Usefulness of the MSG/IFICG/EORTC diagnostic criteria for invasive pulmonary aspergillosis in the clinical management of patients with acute leukemia developing pulmonary infiltrates. Ann Hematol. 2007; 86: 205-10. doi: 10. 1007/s00277-006-0204-3.
19. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis-has the principle been proven? N Engl J Med. 2007; 356: 409-11. doi: 10. 1056/NEJMe068266.
20. Cornely OA, Maerten J, Winston D, Perfect J, Ullman A, Walsh T, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356: 348-59. doi: 10. 1056/NEJMoa061094.
21. Jantunen E, Ruutu P, Niskanen L, Vulin L, Parkkali T, Koukila-Kahkola P, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT patients. Bone Marrow Transplant. 1997; 19: 801-8. doi: 10. 1038/sj. bmt. 1700737.
22. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984; 100: 345-51.
23. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospection, randomized, double-blind study. J Infect Dis. 1995; 171: 1545-52.
24. Marr K, Seidel K, Slavin M, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000; 96: 2055-61.
25. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992; 326: 845-51.
26. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 175: 1459-66.
27. Ribaud P, Chastang C, Latge JP, Buffroy-Lafitte L, Parquet N, Devergie A, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis. 1999; 28: 322-30. doi: 10. 1086/515116.
28. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine. 1993; 72: 78-9. doi: 10. 1097/00005792-199303000-00002.
29. Iwen PC, Reed EC, Armitage JO, Bierman PJ, Kessinger A, Bose JM, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol. 1993; 14: 131-9.
30. Maertens JA, Verhaegen J, Lagrou K, van Eldere J, Boogaerts M, et al. Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001; 97: 1604-10. doi: 10. 1182/blood. V97. 6. 1604.
31. Sherertz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML, et al. Impact of air filtration on nosocomial aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987; 83: 709-18. doi: 10. 1016/0002-9343(87)90902-8.
32. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002; 29: 15-9. doi: 10. 1038/sj. bmt. 1703332.
33. Gil L, Styczynski J, Komarnicki M. Infectious complications in 314 patients after high-dose therapy and autologous stem cell transplantation: risk factors analysis and outcome. Infection. 2007; 35: 421-7. doi: 10. 1007/s15010-007-6350-2.
34. Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant. 2008; Sep 15 e-pub.
35. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34: 909-17. doi: 10. 1086/339202.
36. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B-or triazole-pre-exposed cancer patients with positive cultures for aspergillus. Diagn Miccrobiol Infect Dis. 2005; 52: 15-20. doi: 10. 1016/j. diagmicrobio. 2005. 01. 001.
37. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005; 191: 1350-60. doi: 10. 1086/428780.
38. Park BJ, Kontoyiannis DP, Pappas PG, et al. Comparison of zygomycosis and fusariosis to invasive aspergillosis (IA) among transplant recipients reporting to TRANSNET. In: Program and Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC, Abstract M-666.
39. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006; 108: 2928-36. doi: 10. 1182/blood-2006-03-008706.
40. Chao N, Emerson SG, Weinberg K. Stem cell transplantation (cord blood transplants). Hematology Am Soc Hematol Educ Program. 2004; 354-71. doi: 10. 1182/asheducation-2004. 1. 354.
41. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner KA, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis. 1992; 165: 891-7.
42. Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME study. Int J Antimicrob Agents. 2008; 31: 135-41. doi: 10. 1016/j. ijantimicag. 2007. 10. 001.
43. El-Cheik J, Faucher C, Furst S, Duran S, Berger P, Vey N, et al. High dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplant. Bone Marrow Transplant. 2007; 39: 301-6. doi: 10. 1038/sj. bmt. 1705592.
44. Jansen J, Akard LP, Wach MF, Thompson JM, Dugan MJ, Leslie JK, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses. 2006; 49: 397-404. doi: 10. 1111/j. 1439-0507. 2006. 01264. x.
45. Marr KA, Laverdiere M, Gugel M, Leisenring W. Antifungal therapy decreases sensitivity of Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005; 40: 1762-9. doi: 10. 1086/429921.
46. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999; 93: 3651-6.
47. Griese M, Schams A, Lohmeier KP. Amphotericin B and pulmonary surfactant. Eur J Med Res. 1998; 3: 383-6.
48. Ruijgrok EJ, Vultro AG, van Etten EW. Efficacy of aerosolized amphotericin B deosycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother. 2001; 48: 89-95. doi: 10. 1093/jac/48. 1. 89.
49. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2006; 8: 13-20. doi: 10. 1111/j. 1399-3062. 2006. 00125. x.
50. Rijnders BJ, Cornelissen JS, Slobbe L, Becker MJ, Duorduijn JK, Hop WCJ, et al. Aerosolized liposomal Amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008; 46: 1401-8. doi: 10. 1086/586739.
51. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998; 338: 962-8. doi: 10. 1056/NEJM199804023381405.
52. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized controlled trials. Cancer. 2000; 89: 1611-25. doi: 10. 1002/1097-0142(20001001)89: 7 <1611:: AID-CNCR27> 3. 0. CO; 2-B.
53. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med. 2002; 112: 369-79. doi: 10. 1016/S0002-9343(01)01127-5.
54. Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer. 1998; 83: 291-301. doi: 10. 1002/(SICI)1097-0142(19980715)83: 2< 291:: AID-CNCR13> 3. 3. CO; 2-C.
55. Recommendations of the Center for Disease Control and Prevention, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2000; 6: 659-734.
56. Glassmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol. 2003; 21: 4615-26. doi: 10. 1200/JCO. 2003. 04. 052.
57. Winston DJ, Maziarz RT, Chandrasekar Ph, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med. 2003; 138: 705-13.
58. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004; 103: 1527-33. doi: 10. 1182/blood-2003-08-2644.
59. Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006; 38: 127-34. doi: 10. 1038/sj. bmt. 1705418.
60. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131: 22-8.
61. De Beule KL. Itraconazole: pharmacology, clinical experience, and future development. Int J Antimicrob Agents Chemother. 1996; 6: 175-81. doi: 10. 1016/0924-8579(95)00043-7.
62. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother. 2005; 56: i33-8. doi: 10. 1093/jac/dki222.
63. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad spectrum triazole antifungal. Lancet Infect Dis. 2005; 5: 775-85. doi: 10. 1016/S1473-3099(05)70297-8.
64. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CG, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004; 39: 1407-16. doi: 10. 1086/422312.
65. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichmer L, Cortes J, O'brien S, et al. Open label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006; 50: 143-7. doi: 10. 1128/AAC. 50. 1. 143-147. 2006.
66. Ullman AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft versus host disease. N Engl J Med. 2007; 356: 335-47. doi: 10. 1056/NEJMoa061098.
67. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000; 34: 1032-43. doi: 10. 1345/aph. 19237.
68. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, et al. Results of fluconazole (FLU) vs voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood. 2007; 110: 55a. Abstract #163.
69. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al. Voriconazole therapeutic drug monitoring in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005; 35: 509-13. doi: 10. 1038/sj. bmt. 1704828.
70. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Docosterd LA, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemo. 2007; 51: 137-43. doi: 10. 1128/AAC. 00957-06.
71. Walsh TJ, Raad I, Patterson TF, Chandrashekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007; 44: 2-12. doi: 10. 1086/508774.
72. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007; 27: 1627-36. doi: 10. 1592/phco. 27. 12. 1627.